Oligonucleotides, Antisense
"Oligonucleotides, Antisense" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize.
MeSH Number(s)
D13.150.480
D13.444.600.150.640
D13.695.578.424.480
D27.720.470.530.600.150.640
Concept/Terms
Oligonucleotides, Antisense- Oligonucleotides, Antisense
- Antisense Oligonucleotides
- Anti-Sense Oligonucleotides
- Anti Sense Oligonucleotides
- Oligonucleotides, Anti-Sense
Below are MeSH descriptors whose meaning is more general than "Oligonucleotides, Antisense".
Below are MeSH descriptors whose meaning is more specific than "Oligonucleotides, Antisense".
This graph shows the total number of publications written about "Oligonucleotides, Antisense" by people in Harvard Catalyst Profiles by year, and whether "Oligonucleotides, Antisense" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 6 | 8 |
1995 | 4 | 7 | 11 |
1996 | 8 | 6 | 14 |
1997 | 6 | 6 | 12 |
1998 | 8 | 2 | 10 |
1999 | 4 | 4 | 8 |
2000 | 4 | 9 | 13 |
2001 | 3 | 7 | 10 |
2002 | 3 | 9 | 12 |
2003 | 1 | 23 | 24 |
2004 | 4 | 8 | 12 |
2005 | 2 | 15 | 17 |
2006 | 2 | 9 | 11 |
2007 | 2 | 1 | 3 |
2008 | 0 | 4 | 4 |
2009 | 1 | 9 | 10 |
2010 | 0 | 6 | 6 |
2011 | 2 | 6 | 8 |
2012 | 3 | 6 | 9 |
2013 | 2 | 6 | 8 |
2014 | 4 | 4 | 8 |
2015 | 1 | 5 | 6 |
2016 | 4 | 6 | 10 |
2017 | 5 | 4 | 9 |
2018 | 7 | 4 | 11 |
2019 | 7 | 4 | 11 |
2020 | 7 | 7 | 14 |
2021 | 7 | 2 | 9 |
2022 | 4 | 5 | 9 |
2023 | 1 | 5 | 6 |
Below are the most recent publications written about "Oligonucleotides, Antisense" by people in Profiles.
-
Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice. Acta Neuropathol Commun. 2023 10 19; 11(1):166.
-
A single-cell map of antisense oligonucleotide activity in the brain. Nucleic Acids Res. 2023 08 11; 51(14):7109-7124.
-
A framework for individualized splice-switching oligonucleotide therapy. Nature. 2023 Jul; 619(7971):828-836.
-
Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity. J Immunother Cancer. 2023 05; 11(5).
-
Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. Science. 2023 03 17; 379(6637):1140-1149.
-
Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics. RNA. 2023 04; 29(4):434-445.
-
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. Nucleic Acid Ther. 2023 01; 33(1):17-25.
-
CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood-Brain Barrier and Towards Specific Cellular Targeting. Pharm Res. 2023 Jan; 40(1):77-105.
-
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022 09 22; 387(12):1099-1110.
-
Angiotensinogen: More Than its Downstream Products: Evidence From Population Studies and Novel Therapeutics. JACC Heart Fail. 2022 10; 10(10):699-713.